Archives
-
Ginsenoside Rg1 and Anesthesia-Induced Neuroimmune Disruptio
2026-09-04
A 2025 Journal of Ethnopharmacology study shows that Ginsenoside Rg1 counteracts prolonged isoflurane-associated behavioral, inflammatory, synaptic, intestinal-barrier, and immune abnormalities in mice. Its most important mechanistic advance is evidence that regulatory T cells are required for restoring gut–immune–brain communication, although translation beyond this preclinical model remains unresolved.
-
Pseudo-UTP: Designing Better mRNA Experiments
2026-09-03
Pseudo-UTP enables controlled mRNA synthesis with pseudouridine modification for studies of RNA stability, translation, and immune compatibility. This guide connects nucleotide selection to assay design and interprets what vaccine evidence can—and cannot—establish.
-
Belinostat (PXD101): HDAC Research Guide
2026-09-03
Belinostat (PXD101) is a hydroxamate-type pan-histone deacetylase inhibitor for preclinical epigenetic cancer research. Its reported activity spans biochemical HDAC inhibition, cancer-cell proliferation assays, cell-cycle analysis, and a transgenic bladder-tumor model, but assay-specific IC50 values should not be treated as direct measures of cell death or clinical efficacy.
-
EdU Imaging Kits (488) for S-Phase Research
2026-09-02
EdU Imaging Kits (488) enable rapid, morphology-preserving detection of DNA replication for fluorescence microscopy and flow cytometry. Their click-chemistry workflow is especially useful for separating treatment-driven S-phase suppression from broader changes in viability, cell-cycle distribution, or senescence.
-
Adefovir (GS-0393) Workflows for HBV Research
2026-09-02
Adefovir (GS-0393) supports two complementary research programs: mechanistic hepatitis B virus research and OAT1-mediated renal transporter phenotyping. This workflow-focused guide covers aqueous handling, dose-response design, exposure interpretation, and troubleshooting without conflating research concentrations with clinical pharmacology.
-
B. fragilis, Gut-Brain Cholinergic Signaling, and Seizures
2026-09-01
Jia et al. identify a gut–vagus–brain cholinergic circuit through which Bacteroides fragilis suppresses seizures, linking colonic ChAT-positive cells, vagal transmission, and intestinal Lactobacillus enrichment. Evidence from mouse seizure models and a randomized pediatric trial gives the pathway translational relevance while leaving receptor-level and microbiome-dependence questions for follow-up studies.
-
Annexin V for Apoptosis Assay Workflows
2026-09-01
Build more informative apoptosis assays by pairing calcium-dependent phosphatidylserine recognition with carefully controlled sample handling, labeling, and viability controls. This workflow-oriented guide shows how recombinant Annexin V can move from cultured-cell screening to in situ ischemia–reperfusion research while clarifying its limits and troubleshooting points.
-
Cy5-UTP for Practical RNA Probe Synthesis
2026-08-31
Cy5-UTP converts T7 in vitro transcription into a direct, far-red RNA detection workflow for FISH, expression arrays, and RNA interaction assays. This guide connects probe design and fluorescence optimization with the sequence-dependent RNA interactions revealed in a 2025 MALAT1 study.
-
HyperScript RT SuperMix: Assay Design for HCC
2026-08-31
HyperScript RT SuperMix for qPCR supports structurally challenging RNA and low-input cDNA synthesis for qPCR. This article connects reverse-transcription design with the multi-scale BIRC5–Hippo pathway investigation of hepatocellular carcinoma, emphasizing assay validity rather than product claims alone.
-
Protease Inhibitor Cocktail for Plant Protein Stability
2026-08-30
Protect fragile plant lysates from multi-class proteolysis while preserving phosphorylated and non-phosphorylated targets for Western blotting, co-immunoprecipitation, and kinase assays. This EDTA-free, DMSO-based formulation is especially useful when metal-dependent protein interactions or downstream enzymatic activity must remain intact.
-
LNP mRNA Bleb Structures and Transfection Potency
2026-08-29
The reference study shows that mRNA-rich bleb structures in lipid nanoparticles can be induced through formulation conditions, not only through ionizable-lipid optimization. High-concentration pH 4 sodium citrate improved transfection by preserving encapsulated mRNA, providing a practical formulation variable for both in vitro and in vivo studies.
-
Piroxicam and Deracoxib in Canine Mammary Cancer
2026-08-28
The reference study tested whether piroxicam and deracoxib could directly suppress CMT-U27 canine mammary carcinoma cells and whether combined exposure altered the mechanism of cell death. Using MTT viability testing and flow cytometry, the authors identified stronger combination-associated cytotoxicity, apoptosis, and G0/G1 accumulation, while also highlighting the limits of extrapolating high-concentration in vitro findings to clinical treatment.
-
A Broad-Spectrum mRNA Vaccine for Omicron and SARS-CoV
2026-08-28
Guan and colleagues developed a lipid nanoparticle-encapsulated mRNA vaccine that replaces the mutation-prone Omicron receptor-binding domain with a conserved SARS-CoV RBD. In mice, this chimeric design generated cross-reactive neutralizing antibodies and protection against both SARS-CoV-2 Omicron and SARS-CoV, supporting antigen engineering as a strategy for broader coronavirus vaccine coverage.
-
Angiotensin Peptides and SARS-CoV-2 Spike Binding
2026-08-27
The 2025 reference study reports that naturally occurring angiotensin peptides can increase SARS-CoV-2 spike-protein binding to host receptors, with the strongest effects associated with shorter, N-terminally truncated peptides such as angiotensin IV. Its antibody-based binding experiments identify peptide length and Tyr4 modification as important variables, while also emphasizing that biochemical binding does not establish enhanced viral infection in cells or patients.
-
NPT1-Mediated Faropenem Transport in Kidney
2026-08-27
The 2000 reference study provided the first molecular evidence that human NPT1, a renal apical sodium–phosphate transporter, can mediate p-aminohippuric acid and several organic anions, including faropenem. Its heterologous-cell uptake model established a mechanistic link between renal apical transport and β-lactam disposition while also defining important limits for interpreting antimicrobial or pharmacokinetic outcomes.